CSIMarket
 


Seelos Therapeutics inc   (SEEL)
Other Ticker:  
 

Cumulative Seelos Therapeutics Inc 's Quick Ratio for Trailing Twelve Months Period

SEEL's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

SEEL Quick Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth 54.73 % 69.13 % 312.16 % 287.97 % 203.58 %
Y / Y Cash & cash equivalent Growth -80.71 % -91.53 % -85.84 % -77.24 % -80.27 %
Quick Ratio for Trailing Twelve Months Period 0.15 0.24 0.47 1.03 2.14
Total Ranking # 1791 # 2572 # 2176 # 1677 # 1333
Seq. Current Liabilities Growth 10.19 % -37.04 % 43.14 % 55.82 % 20.45 %
Seq. Cash & cash equivalent Growth 15.94 % -55.78 % -58.44 % -9.49 % -49.09 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Due to increase in Current Liabilities in the IV. Quarter to $39 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 0.15 below Seelos Therapeutics Inc average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 205 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Seelos Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about SEEL
Quick Ratio SEEL in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 206
Sector # 452
S&P 500 # 2013


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
8.94 2.64 0.15
(Mar 31 2022)   (Dec 31 2023)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Intercept Pharmaceuticals inc   0.41 
Merck and Co Inc   0.41 
Accustem Sciences Inc   0.40 
Flora Growth Corp   0.40 
Journey Medical Corporation  0.39 
Tenx Keane Acquisition  0.37 
Innovation Pharmaceuticals Inc   0.37 
Eagle Pharmaceuticals inc   0.37 
Comera Life Sciences Holdings Inc   0.34 
Ensysce Biosciences Inc   0.34 
Emergent Biosolutions Inc   0.34 
Abbvie inc   0.32 
Elanco Animal Health Inc  0.31 
Jaguar Health inc   0.31 
Dmk Pharmaceuticals Corporation  0.30 
Integrated Biopharma Inc  0.30 
Panbela Therapeutics Inc   0.28 
Grifols Sa  0.28 
Aytu Biopharma Inc   0.28 
Checkpoint Therapeutics Inc   0.28 
Novan Inc   0.28 
Athenex Inc   0.27 
Orgenesis Inc   0.27 
Teva Pharmaceutical Industries Limited  0.27 
Nabriva Therapeutics Plc  0.26 
Agile Therapeutics Inc  0.25 
Seelos Therapeutics inc   0.25 
Abvc Biopharma Inc   0.24 
Lucy Scientific Discovery Inc   0.24 
Aditxt Inc   0.23 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com